Rivastigmine for HIV-associated neurocognitive disorders: A randomized crossover pilot study

Neurology

Volumn 80, Issue 6, 2013, Pages 553-560

  Simioni, Samanta ^a   Cavassini, Matthias ^a   Annoni, Jean Marie ^b   Métral, Mélanie ^c   Iglesias, Katia ^a   Abraham, Aline Rimbault ^c   Jilek, Samantha ^a   Calmy, Alexandra ^d   Müller, Hubertus ^c   Fayet Mello, Aurélie ^a   Giacobini, Ezio ^c   Hirschel, Bernard ^d   Du Pasquier, Renaud A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hopital Cantonal de Fribourg   (Switzerland)

^c HUG   (Switzerland)

^d UNAIDS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; PLACEBO; RIVASTIGMINE;

ADULT; ADVERSE OUTCOME; AGED; ALZHEIMER DISEASE ASSESSMENT SCALE; ANXIETY; ARTICLE; ATTENTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; INFORMATION PROCESSING; LABORATORY TEST; MALE; MOTOR PERFORMANCE; NAUSEA; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WORKING MEMORY;

AIDS DEMENTIA COMPLEX; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PILOT PROJECTS;

EID: 84873622796     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182815497     Document Type: Article

References (36)

1. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011;17:3-16.
2. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142.
3. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75:2087-2096.
4. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24:1243-1250.
5. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998;65:29-33.
6. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005;19:127-135.
7. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 2005;19:407-411.
8. Clifford DB, Fagan AM, Holtzman DM, et al. CSF bio-markers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009;73:1982-1987.
9. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 2005;65:1490-1492.
10. An SF, Giometto B, Groves M, et al. Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS. J Neuropathol Exp Neurol 1997;56:1262-1268.
11. Giunta B, Ehrhart J, Townsend K, et al. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res Bull 2004;64:165-170.
12. Koutsilieri E, Czub S, Scheller C, et al. Brain choline acetyltransferase reduction in SIV infection: an index of early dementia? Neuroreport 2000;11:2391-2393.
13. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799.
14. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
15. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-939.
16. Sahakian BJ, Owen AM. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med 1992;85:399-402.
17. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsy-chological Test Battery: Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press; 1993.
18. Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual. New York: Psychological Corporation; 1981.
19. Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:273-278.
20. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005;19:1367-1374.
21. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
22. Scott-Lennox JA, Wu AW, Boyer JG, Ware JE Jr. Reliability and validity of French, German, Italian, Dutch, and UK English translations of the Medical Outcomes Study HIV Health Survey. Med Care 1999;37:908-925.
23. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. Neurology 1997;49:142-146.
24. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000;54:233-235.
25. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment.Neurology 1998;50:645-651.
26. Letendre SL, Woods SP, Ellis RJ, et al. Lithium improves HIV-associated neurocognitive impairment. AIDS 2006;20:1885-1888.
27. Schifitto G, Zhong J, Gill D, et al. Lithium therapy for human immunodeficiency virus type 1-associated neuro-cognitive impairment. J Neurovirol 2009;15:176-186.
28. Navia BA, Dafni U, Simpson D, et al. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998;51:221-228.
29. Heseltine PN, Goodkin K, Atkinson JH, et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol 1998;55:41-51.
30. Schifitto G, Sacktor N, Marder K, et al. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment: Neurological AIDS Research Consortium. Neurology 1999;53:391-396.
31. Clifford DB, McArthur JC, Schifitto G, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 2002;59:1568-1573.
32. Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsycho-logical and proton magnetic resonance spectroscopy study. AIDS 2007;21:1877-1886.
33. Zhao Y, Navia BA, Marra CM, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials 2010;11:59-67.
34. Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 2011;77:1135-1142.
35. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-564.
36. Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69:S14-S22.